secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2021-08-04T23:59:59+00:00
Accession:  0001564590-21-040826
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotechnologies Q2 revenue $38.5M, +83% YoY; raises FY2021 guidance to $148M-$155M
--------------------------------------------------------------------------------

- Revenue $38.5M (+83% YoY); sequencing revenue $18.6M (+132%), development revenue $20.0M (+53%).
- Net loss $49.3M vs $33.5M YoY; adjusted EBITDA loss $35.6M vs $28.5M.
- FY2021 revenue guidance raised to $148M-$155M (prior $145M-$155M).
- clonoSEQ volume +75% YoY; signed agreements with Vaccibody and Moderna for T-cell data and COVID vaccine T-cell response measurement.
- Cash and marketable securities $689.5M as of June 30, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000156459021040826/0001564590-21-040826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000156459021040826/adpt-8k_20210804.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-040826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer